Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Edgewise Therapeutics Inc (NQ: EWTX )

31.98 +0.03 (+0.09%)
Streaming Delayed Price Updated: 4:00 PM EST, Nov 21, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Edgewise Therapeutics Inc

< Previous 1 2 3 4 5 6 Next >
Edgewise Therapeutics Announces Initiation of GRAND CANYON, a Global Pivotal Study of EDG-5506 in Becker Muscular Dystrophy (Becker)
From Edgewise Therapeutics
Via Business Wire
Edgewise Therapeutics Begins Dosing First-in-Human Phase 1 Trial of EDG-7500, its Lead Clinical Candidate for Hypertrophic Cardiomyopathy (HCM) and Other Serious Diseases of Cardiac Diastolic Dysfunction
From Edgewise Therapeutics
Via Business Wire
Where Edgewise Therapeutics Stands With Analysts
Via Benzinga
Analyst Ratings for Edgewise Therapeutics
Via Benzinga
Edgewise Therapeutics: Q1 Earnings Insights
Via Benzinga
Edgewise Therapeutics Reports Second Quarter 2023 Financial Results and Recent Business Highlights
From Edgewise Therapeutics
Via Business Wire
Why Walgreens Shares Are Trading Lower By Over 9%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Gainers Tivic Health Systems, Inc. (NASDAQ: TIVC) shares jumped 105% to $0.2050 after the company signed a distribution agreement with Cardinal Health. 
Via Benzinga
CIRCOR International, Enovix, Edgewise Therapeutics And Other Big Stocks Moving Higher On Tuesday
U.S. stocks traded higher, with the Dow Joned gaining around 100 points on Tuesday. Here are some big stocks recording gains in today’s session. 
Via Benzinga
Edgewise Therapeutics Touts Positive Data From Investigational Drug In Form Of Muscular Dystrophy
Edgewise Therapeutics Inc (NASDAQ: EWTX) released 12-month topline results from the ARCH study, an open-label, single-center study assessing EDG-5506 in adults with  
Via Benzinga
Edgewise Therapeutics Announces Positive 12-Month Topline Results from the ARCH Open Label Study of EDG-5506 in Adults with Becker Muscular Dystrophy (BMD)
From Edgewise Therapeutics
Via Business Wire
Edgewise Therapeutics to Present at the Goldman Sachs Global Healthcare Conference
From Edgewise Therapeutics
Via Business Wire
Edgewise Therapeutics Reports First Quarter 2023 Financial Results and Recent Business Highlights
From Edgewise Therapeutics
Via Business Wire
Edgewise Therapeutics to Present at Upcoming Investor Conferences
From Edgewise Therapeutics
Via Business Wire
Flexing On Muscular Dystrophy, Analyst Expects Almost 200% Upside For Edgewise Therapeutics
Truist initiated coverage on Edgewise Therapeutics Inc (NASDAQ: EWTX) with a Buy rating and a  
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For May 1, 2023
Via Benzinga
Xerox, Hubbell, Spotify And Other Big Stocks Moving Higher On Tuesday
U.S. stocks traded lower, with the Nasdaq Composite dropping around 100 points on Tuesday. Here are some big stocks recording gains in today’s session. 
Via Benzinga
Tiziana Life Sciences Has Only Fully Human Anti-CD3 mAB In Clinical Studies, Could Be Poised To Improve Care For Patients With Severe Multiple Sclerosis
Tiziana Life Sciences (NASDAQ: TLSA), a London-based biotechnology company, is developing a first-in-class drug, Foralumab. Foralumab is the only fully human anti-CD3 monoclonal antibody (mAb) at the... 
Via Benzinga
Edgewise Therapeutics Announces Journal of Clinical Investigation Publication of Key Preclinical Data Linking Modulation of Fast Skeletal Muscle Contraction to Protection of Skeletal Muscle in Models of Duchenne Muscular Dystrophy (DMD)
From Edgewise Therapeutics
Via Business Wire
Top 5 Health Care Stocks That Preparing To Pump This Quarter
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies. 
Via Benzinga
Edgewise Therapeutics to Present at the Stifel 2023 CNS Days on March 28, 2023
From Edgewise Therapeutics
Via Business Wire
Edgewise Therapeutics to Present on EDG-5506 for Becker and Duchenne Muscular Dystrophy (BMD, DMD) at the 2023 Annual MDA Clinical and Scientific Conference
From Edgewise Therapeutics
Via Business Wire
Edgewise Therapeutics Appoints Industry Veteran Jonathan C. Fox, M.D., Ph.D., FACC to its Board of Directors
From Edgewise Therapeutics
Via Business Wire
Edgewise Therapeutics to Present at the Cowen 43rd Annual Health Care Conference on March 8, 2023
From Edgewise Therapeutics
Via Business Wire
Edgewise Therapeutics Announces Upcoming Presentation at the American College of Cardiology's 72nd Annual Scientific Session Together with World Congress of Cardiology
From Edgewise Therapeutics
Via Business Wire
Edgewise Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Recent Business Highlights
From Edgewise Therapeutics
Via Business Wire
Edgewise Therapeutics to Present at the SVB Securities Global Biopharma Conference on February 14, 2023
From Edgewise Therapeutics
Via Business Wire
Edgewise Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference on January 10, 2023
From Edgewise Therapeutics
Via Business Wire
Edgewise Therapeutics to Showcase Novel Cardiac Program at Virtual Investor Event on Tuesday, January 3, 2023
From Edgewise Therapeutics
Via Business Wire
Edgewise Therapeutics Appoints Marc Semigran, M.D., As Chief Development Officer
From Edgewise Therapeutics
Via Business Wire
Edgewise Therapeutics to Present at Upcoming Investor Conferences
From Edgewise Therapeutics
Via Business Wire
< Previous 1 2 3 4 5 6 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.